Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.
Merck & Co. has achieved trial success for two of its biggest pipeline hopes in cardiovascular medicine, adding weight to its efforts to build a multi-blockbuster presence in the field.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
